Patent details
301211
Product Name:
Olipudase alfa
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301211
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP3482767
Status:
SPC granted but not yet in force
Application number:
301211
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/22/1659
Marketing Authorization Type:
EEA
Marketing Authorization Date:
27/06/2022
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
20/12/2022
First Marketing Authorization date:
27/06/2022
Grant date:
02/02/2023
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
21/12/2022
SPC/SPC Extension Expiration Date:
27/08/2035
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
20/12/2022
Name:
Icahn School of Medicine at Mount Sinai
Address:
One Gustave L. Levy Place, NEW YORK, NY 10029, United States of America (US)
From:
20/12/2022
Name:
Genzyme Corporation
Address:
450 Water Street, 02141, Cambridge, MA, United States of America (US)
Agent
Name:
ir. B.Ch. Ledeboer c.s
From:
20/12/2022
Address:
V.O.
Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
SPC
Journal edition number:
06/23
Publication date:
08/02/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
2
Bulletin Heading:
SPC
Journal edition number:
52/22
Publication date:
28/12/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Annual Fee
Annual Fee(s) Due Date:
31/08/2030
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date
Document type
Document Description
Number of pages
File Type
02/02/2023
Certificate
Certificate
1
PDF
/0/2/2/5/4/0800845220/docs/301211_0_spcmedcertificate20230202111104528.pdf
02/02/2023
Outgoing Correspondence
Decision grant
1
PDF
/0/2/2/5/4/0800845220/docs/301211_1_529285l504a.pdf
21/12/2022
Outgoing Correspondence
Confirmation receipt request
1
PDF
/0/2/2/5/4/0800845220/docs/301211_2_521637l174.pdf
20/12/2022
SPC Documents
Annex SPC
4
PDF
/0/2/2/5/4/0800845220/docs/301211_3_supplprotectioncertificate20221221105000568.pdf
20/12/2022
SPC Documents
Annex SPC
16
PDF
/0/2/2/5/4/0800845220/docs/301211_4_supplprotectioncertificate20221221105000601.pdf
20/12/2022
Application Form
First filed application form
3
PDF
/0/2/2/5/4/0800845220/docs/301211_5_applicationform20221221105000447.pdf
20/12/2022
SPC Documents
Summary of the characteristics of the product
22
PDF
/0/2/2/5/4/0800845220/docs/301211_6_supplprotectioncertificate20221229024731834.pdf
20/12/2022
SPC Documents
Marketing Authorization SPC
4
PDF
/0/2/2/5/4/0800845220/docs/301211_7_supplprotectioncertificate20221229024522177.pdf
20/12/2022
SPC Documents
Accompanying letter SPC
2
PDF
/0/2/2/5/4/0800845220/docs/301211_8_supplprotectioncertificate20221221105000499.pdf